Poxel S.A. (PXXLF)
| Previous Close | 2.6000 |
| Open | 2.6000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.6000 - 2.6000 |
| 52 Week Range | 2.6000 - 9.2600 |
| Volume | |
| Avg. Volume | 5 |
| Market Cap | 65.223M |
| Beta (5Y Monthly) | 1.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8710 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Thomson Reuters StreetEvents
Edited Transcript of POXEL.PA earnings conference call or presentation 21-Sep-22 12:45pm GMT
Half Year 2022 Poxel SA Earnings Call
- Business Wire
Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone
LYON, France, September 21, 2022--POXEL SA (Euronext : POXEL - FR0012432516), clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced positive histology results for DESTINY-1 (Deuterium-stabilized R-pioglitazone [PXL065] Efficacy and Safety Trial In NASH), the dose-ranging Phase 2 trial of PXL065 for the treatment of NASH. PXL
- Business Wire
Poxel Reports Financial Results for First Half 2022 and Provides a Corporate Update
LYON, France, September 21, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2022 and provided a corporate update.
